RY 172.7 -0.1792% SHOP 152.38 -3.7762% TD 74.49 -0.4144% ENB 58.66 0.2906% BN 80.21 0.2124% TRI 235.76 -0.7034% CNQ 42.27 -1.3305% CP 102.81 -2.4851% CNR 145.02 -0.9426% BMO 139.15 0.5855% BNS 77.045 -0.149% CSU 4497.2998 0.6756% CM 92.23 -0.335% MFC 43.28 0.8858% ATD 79.0 -1.1882% NGT 53.35 -1.8038% TRP 65.26 0.215% SU 49.61 -1.411% WCN 251.65 -0.2181% L 191.14 0.1205%
Last update at 2024-12-19T18:50:00Z
Exclusive: Adani, under bribery scrutiny, pressed by Bangladesh to reopen power deal
Thu 19 Dec 24, 02:05 AMBritain joins trans-Pacific pact in biggest post-Brexit trade deal
Sun 15 Dec 24, 12:05 AMMicroStrategy secures Nasdaq-100 inclusion after bitcoin-fueled stock surge
Sat 14 Dec 24, 02:15 AMThe Onion's purchase of Alex Jones' Infowars stopped by US judge
Wed 11 Dec 24, 05:09 AMGermany's Scholz to submit parliament request to hold confidence vote
Wed 11 Dec 24, 05:02 AMAustralia's Perpetual sinks on adverse tax ruling over KKR deal
Tue 10 Dec 24, 12:51 AMUS judge weighs fate of the Onion's buyout of Infowars
Mon 09 Dec 24, 11:06 AMInsulet wins $452 mln US verdict against EOFlow in insulin pump secrets case
Thu 05 Dec 24, 04:08 PMStanford overcomes deep trouble to bury Utah Valley
Wed 04 Dec 24, 05:17 AMUS Senate confirms Biden-picked judges in DC, Pennsylvania
Tue 03 Dec 24, 10:09 PM| Breakdown | 2023-10-31 | 2022-10-31 | 2021-10-31 | 2020-10-31 | 2019-10-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-10-31 | 2022-10-31 | 2021-10-31 | 2020-10-31 | 2019-10-31 |
| Income before tax | 1339.00M | 1504.00M | 1360.00M | 842.00M | 919.00M |
| Minority interest | - | - | - | - | - |
| Net income | 1240.00M | 1254.00M | 1210.00M | 719.00M | 1071.00M |
| Selling general administrative | 1634.00M | 1637.00M | 1619.00M | 1496.00M | 1460.00M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 3465.00M | 3722.00M | 3407.00M | 2837.00M | 2805.00M |
| Reconciled depreciation | 271.00M | 317.00M | 321.00M | 308.00M | 238.00M |
| Ebit | 1434.00M | 1618.00M | 1347.00M | 846.00M | 941.00M |
| Ebitda | 1705.00M | 1905.00M | 1762.00M | 1228.00M | 1231.00M |
| Depreciation and amortization | 271.00M | 287.00M | 415.00M | 382.00M | 290.00M |
| Non operating income net other | - | -30.00000M | 94.00M | 74.00M | 52.00M |
| Operating income | 1350.00M | 1618.00M | 1347.00M | 846.00M | 941.00M |
| Other operating expenses | 5483.00M | 5230.00M | 4972.00M | 4493.00M | 4222.00M |
| Interest expense | 95.00M | 84.00M | 81.00M | 78.00M | 74.00M |
| Tax provision | 99.00M | 250.00M | 150.00M | 123.00M | -152.00000M |
| Interest income | 51.00M | 9.00M | 79.00M | 70.00M | 36.00M |
| Net interest income | -44.00000M | -75.00000M | -79.00000M | -70.00000M | -38.00000M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 99.00M | 250.00M | 150.00M | 123.00M | -152.00000M |
| Total revenue | 6833.00M | 6848.00M | 6319.00M | 5339.00M | 5163.00M |
| Total operating expenses | 2115.00M | 2104.00M | 2060.00M | 1991.00M | 1864.00M |
| Cost of revenue | 3368.00M | 3126.00M | 2912.00M | 2502.00M | 2358.00M |
| Total other income expense net | 33.00M | -114.00000M | 13.00M | -4.00000M | -22.00000M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 1240.00M | 1254.00M | 1210.00M | 719.00M | 1071.00M |
| Net income applicable to common shares | - | 1254.00M | 1210.00M | 719.00M | 1071.00M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2024-10-31 | 2023-10-31 | 2022-10-31 | 2021-10-31 | 2020-10-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-10-31 | 2023-10-31 | 2022-10-31 | 2021-10-31 | 2020-10-31 |
| Total assets | 11846.00M | 10763.00M | 10516.00M | 10705.00M | 9627.00M |
| Intangible assets | 547.00M | 475.00M | 821.00M | 981.00M | 831.00M |
| Earning assets | - | - | - | - | - |
| Other current assets | 334.00M | 274.00M | 282.00M | 222.00M | 216.00M |
| Total liab | 5948.00M | 4918.00M | 5227.00M | 5316.00M | 4754.00M |
| Total stockholder equity | 5898.00M | 5845.00M | 5289.00M | 5389.00M | 4873.00M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 1310.00M | 680.00M | 784.00M | 821.00M | 652.00M |
| Common stock | 3.00M | 3.00M | 3.00M | 3.00M | 3.00M |
| Capital stock | - | 3.00M | 3.00M | 3.00M | 3.00M |
| Retained earnings | 750.00M | 782.00M | 324.00M | 348.00M | 81.00M |
| Other liab | - | - | 633.00M | 879.00M | 876.00M |
| Good will | 4477.00M | 3960.00M | 4773.00M | 4956.00M | 4433.00M |
| Other assets | - | - | 670.00M | 820.00M | 601.00M |
| Cash | 1329.00M | 1590.00M | 1053.00M | 1484.00M | 1441.00M |
| Cash and equivalents | - | - | 1053.00M | 1484.00M | 1441.00M |
| Total current liabilities | 1895.00M | 1603.00M | 1861.00M | 1708.00M | 1467.00M |
| Current deferred revenue | - | 505.00M | 461.00M | 441.00M | 386.00M |
| Net debt | 2061.00M | 1145.00M | 1716.00M | 1245.00M | 918.00M |
| Short term debt | 45.00M | - | 36.00M | 0.00000M | 75.00M |
| Short long term debt | - | - | 36.00M | - | 75.00M |
| Short long term debt total | 3390.00M | 2735.00M | 2769.00M | 2729.00M | 2359.00M |
| Other stockholder equity | 5450.00M | 5387.00M | 5325.00M | 5320.00M | 5311.00M |
| Property plant equipment | - | - | 1100.00M | 945.00M | 845.00M |
| Total current assets | 3959.00M | 4186.00M | 3778.00M | 3799.00M | 3415.00M |
| Long term investments | - | 164.00M | 195.00M | 185.00M | 158.00M |
| Net tangible assets | - | - | 516.00M | 433.00M | 440.00M |
| Short term investments | - | - | 0.00000M | 91.00M | 158.00M |
| Net receivables | 1324.00M | 1291.00M | 1405.00M | 1172.00M | 1038.00M |
| Long term debt | - | 2735.00M | 2733.00M | 2729.00M | 2284.00M |
| Inventory | 972.00M | 1031.00M | 1038.00M | 830.00M | 720.00M |
| Accounts payable | 540.00M | 418.00M | 580.00M | 446.00M | 354.00M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -305.00000M | -327.00000M | -363.00000M | -282.00000M | -522.00000M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | 3.00M | 3.00M | 3.00M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | 324.00M | 348.00M | 81.00M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 910.00M | 708.00M | 670.00M | 820.00M | 776.00M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 7887.00M | 6577.00M | 6738.00M | 6906.00M | 6212.00M |
| Capital lease obligations | - | - | - | - | - |
| Long term debt total | - | - | 2733.00M | 2729.00M | 2284.00M |
| Breakdown | 2023-10-31 | 2022-10-31 | 2021-10-31 | 2020-10-31 | 2019-10-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-10-31 | 2022-10-31 | 2021-10-31 | 2020-10-31 | 2019-10-31 |
| Investments | -310.00000M | 9.00M | -10.00000M | -29.00000M | -26.00000M |
| Change to liabilities | - | 121.00M | 64.00M | 31.00M | 52.00M |
| Total cashflows from investing activities | - | -338.00000M | -749.00000M | -147.00000M | -1590.00000M |
| Net borrowings | - | 26.00M | 356.00M | -45.00000M | 596.00M |
| Total cash from financing activities | -930.00000M | -1372.00000M | -696.00000M | -717.00000M | -299.00000M |
| Change to operating activities | - | -30.00000M | 112.00M | -152.00000M | -26.00000M |
| Net income | 1240.00M | 1254.00M | 1210.00M | 719.00M | 1071.00M |
| Change in cash | 537.00M | -434.00000M | 43.00M | 59.00M | -866.00000M |
| Begin period cash flow | 1056.00M | 1490.00M | 1447.00M | 1388.00M | 2254.00M |
| End period cash flow | 1593.00M | 1056.00M | 1490.00M | 1447.00M | 1388.00M |
| Total cash from operating activities | 1772.00M | 1312.00M | 1485.00M | 921.00M | 1021.00M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 271.00M | 317.00M | 321.00M | 308.00M | 238.00M |
| Other cashflows from investing activities | - | -4.00000M | -5.00000M | 1.00M | -1409.00000M |
| Dividends paid | -265.00000M | -250.00000M | -236.00000M | -222.00000M | -206.00000M |
| Change to inventory | -33.00000M | -248.00000M | -136.00000M | -68.00000M | -36.00000M |
| Change to account receivables | 132.00M | -321.00000M | -128.00000M | -107.00000M | -106.00000M |
| Sale purchase of stock | -575.00000M | -1139.00000M | -788.00000M | -469.00000M | -723.00000M |
| Other cashflows from financing activities | -122.00000M | 1828.00M | -83.00000M | -41.00000M | -24.00000M |
| Change to netincome | - | 219.00M | 42.00M | 247.00M | -149.00000M |
| Capital expenditures | 298.00M | 291.00M | 189.00M | 119.00M | 156.00M |
| Change receivables | - | -321.00000M | -128.00000M | -107.00000M | -106.00000M |
| Cash flows other operating | - | 59.00M | -112.00000M | -209.00000M | -49.00000M |
| Exchange rate changes | - | - | 3.00M | 2.00M | 2.00M |
| Cash and cash equivalents changes | - | -398.00000M | 43.00M | 59.00M | -866.00000M |
| Change in working capital | -116.00000M | -478.00000M | -88.00000M | -296.00000M | -388.00000M |
| Stock based compensation | 111.00M | 125.00M | 110.00M | 83.00M | 72.00M |
| Other non cash items | 322.00M | 86.00M | -82.00000M | 78.00M | 283.00M |
| Free cash flow | 1474.00M | 1021.00M | 1296.00M | 802.00M | 865.00M |
Sector: Healthcare Industry: Diagnostics & Research
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| A Agilent Technologies Inc |
0.86 0.65% | 133.87 | 31.97 | 25.84 | 6.23 | 6.96 | 6.62 | 23.01 |
| TMO Thermo Fisher Scientific Inc |
2.81 0.54% | 518.99 | 34.71 | 23.87 | 4.62 | 4.43 | 5.29 | 20.89 |
| DHR Danaher Corporation |
-0.38 0.17% | 227.92 | 29.09 | 28.01 | 5.67 | 3.20 | 6.00 | 19.09 |
| IDXX IDEXX Laboratories Inc |
-0.4 0.10% | 410.36 | 49.99 | 45.66 | 11.29 | 27.85 | 11.46 | 34.46 |
| IQV IQVIA Holdings Inc |
-0.225 0.12% | 190.75 | 37.82 | 19.68 | 2.76 | 7.20 | 3.61 | 17.03 |
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment focuses on genomics, nucleic acid contract manufacturing and research and development, pathology, companion diagnostics, reagent partnership, and biomolecular analysis businesses. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and offers services portfolio, including repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, and consulting services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.
5301 Stevens Creek Boulevard, Santa Clara, CA, United States, 95051
| Name | Title | Year Born |
|---|---|---|
| Mr. Michael R. McMullen | CEO, Pres & Director | 1961 |
| Mr. Robert W. McMahon | Sr. VP & CFO | 1969 |
| Mr. Jacob Thaysen | Sr. VP and Pres of Life Sciences & Applied Markets Group | 1975 |
| Mr. Samraat S. Raha | Sr. VP and Pres of Diagnostics & Genomics Group | 1973 |
| Mr. Padraig McDonnell | Sr. VP & Pres of Agilent Cross Lab Group | NA |
| Mr. Rodney Gonsalves | Principal Accounting Officer, VP & Corp. Controller | 1966 |
| Dr. Darlene J. S. Solomon Ph.D. | CTO & Sr. VP | 1959 |
| Mr. Michael Tang | Sr. VP, Gen. Counsel & Sec. | 1974 |
| Mr. Dominique P. Grau | Sr. VP of HR & Global Communications | 1959 |
| Ms. Allison Ballmer | Sr. VP of Strategy & Corp. Devel. | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
CA 
AU
UK
US
NZ
Please wait processing your request...